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Background: FOXO transcription factors control cellular levels of reactive oxygen species (ROS) which critically
contribute to cell survival and cell death in neuroblastoma. In the present study we investigated the regulation of
C10orf10/DEPP by the transcription factor FOXO3. As a physiological function of C10orf10/DEPP has not been
described so far we analyzed its effects on cellular ROS detoxification and death sensitization in human
neuroblastoma cells.
Methods: The effect of DEPP on cellular ROS was measured by catalase activity assay and live cell fluorescence
microscopy using the ROS-sensitive dye reduced MitoTracker Red CM-H2XROS. The cellular localization of DEPP was
determined by confocal microscopy of EYFP-tagged DEPP, fluorescent peroxisomal- and mitochondrial probes and
co-immunoprecipitation of the PEX7 receptor.
Results: We report for the first time that DEPP regulates ROS detoxification and localizes to peroxisomes and
mitochondria in neuroblastoma cells. FOXO3-mediated apoptosis involves a biphasic ROS accumulation. Knockdown
of DEPP prevented the primary and secondary ROS wave during FOXO3 activation and attenuated FOXO3- and
H2O2-induced apoptosis. Conditional overexpression of DEPP elevates cellular ROS levels and sensitizes to H2O2 and
etoposide-induced cell death. In neuronal cells, cellular ROS are mainly detoxified in peroxisomes by the enzyme
CAT/catalase. As DEPP contains a peroxisomal-targeting-signal-type-2 (PTS2) sequence at its N-terminus that allows
binding to the PEX7 receptor and import into peroxisomes, we analyzed the effect of DEPP on cellular detoxification by
measuring enzyme activity of catalase. Catalase activity was reduced in DEPP-overexpressing cells and significantly
increased in DEPP-knockdown cells. DEPP directly interacts with the PEX7 receptor and localizes to the peroxisomal
compartment. In parallel, the expression of the transcription factor peroxisome proliferator-activated receptor gamma
(PPARG), a critical regulator of catalase enzyme activity, was strongly upregulated in DEPP-knockdown cells.
Conclusion: The combined data indicate that in neuroblastoma DEPP localizes to peroxisomes and mitochondria and
impairs cellular ROS detoxification, which sensitizes tumor cells to ROS-induced cell death.
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Decidual Protein induced by Progesterone (DEPP) was ori-
ginally identified as fasting- and progesterone-induced
gene. DEPP is regulated via progesterone in endometrial
stromal cells and via insulin levels in adipose tissue and
liver and is induced in malignant glioma cells in response
to hypoxic stress. It is highly expressed in various tissues
including placenta, ovary, kidney, white adipose and liver.
The amino acid sequence of DEPP contains a peroxisomal-
targeting-signal-type-2 (PTS2) sequence, which suggests
that DEPP may be imported into peroxisomes. However,
the physiological functions of DEPP remain largely un-
known [1-3].
In neuroblastoma cells an increased activity of the
phosphatidylinositol-3 kinase (PI3K) protein kinase B
(PKB/AKT) pathway was reported that contributes to
therapy resistance and is associated with phosphory-
lation and functional inactivation of the transcription fac-
tor FOXO3 [4,5]. Phosphorylation of FOXO3 by PKB at
distinct amino acids leads to its association with 14-3-3
proteins, resulting in export from the nucleus and as a
consequence thereof loss of target gene regulation in
neuroblastoma cells [6]. Phosphorylation of FOXO3 by
stress-induced kinases such as mammalian Ste20-like
kinase (MST1) or c-Jun N-terminal kinase (JNK) in turn
stimulates nuclear entry, leading to the activation or re-
pression of target genes that affect growth, cell cycle
progression, apoptosis and longevity [7-9].
In neuroblastoma cells, FOXO3 regulates cellular apop-
tosis by activating the two BH3-only proteins PMAIP1/
Noxa and BCL2L11/Bim [5] and sensitizes these tumor
cells to chemotherapy-induced cell death by repressing
the IAP-family member BIRC5/Survivin [10]. Recently we
also demonstrated that DNA-damaging agents activate
FOXO3 and thereby cause reactive oxygen species (ROS)
formation at the mitochondria due to uncoupling of mito-
chondrial respiration through the BH3-only protein Bim
[11]. ROS are generated as side products of mitochondrial
respiration [12]. Under normal conditions, low amounts
of ROS are mainly detoxified in peroxisomes by the en-
zyme CAT/catalase [13], in the mitochondria by super-
oxide dismutase (SOD2) as well as by members of the
sestrin family [6,9] and by peroxiredoxins which are lo-
cated in diverse organelles dependent on the cell type [14].
Catalase converts hydrogen peroxide to water and oxygen
[15] and is also described as a direct transcriptional target
of FOXO transcription factors in various cell types [16,17].
It is not regulated in neuroblastoma cells [11]. High levels
of cellular ROS cause oxidation of proteins, nucleic
acids and intracellular membranes thereby impairing
cell growth, cellular survival and proliferation [18,19].
The transcription factor peroxisome proliferator-activated
receptor gamma (PPARG) was described to be critical for
the regulation of ROS steady state levels, as it directlyinfluences the expression of several ROS-detoxifying en-
zymes, among them also catalase [20]. The PPARG pro-
moter is repressed by FOXO1 in adipocytes - on the other
hand PPARG can also repress the transcriptional activity
of FOXO1 [21,22].
Also beta-Catenin, which is regulated via the Wnt-
pathway [23], represses PPARG expression and interacts
with both, FOXO3 and PPARG via its TCF/Lef1 binding
site (reviewed in [24]). DEPP may affect Wnt-signaling
and thereby PPARG expression via its Pro-Pro-Pro-Ser-
Pro (PPPSP) motif that has been shown to activate the
Wnt-pathway [3,25].
In the present study we investigated the regulation of
DEPP by FOXO3 in human neuroblastoma cells and ad-
dressed its effects on cellular ROS household and tumor
growth.
Results
FOXO3 regulates DEPP expression on mRNA and protein
level in human neuroblastoma cells
DEPP was identified as a FOXO3-induced gene by
Affymetrix gene-chip expression profiling analysis in cells
which stably express a 4-hydroxy-tamoxifen-inducible
(4OHT), PKB-phosphorylation-independent FOXO3(A3)
ERtm transgene. After activation of FOXO3 by treatment
with 100 nM 4OHT for 3 hours, DEPP expression was in-
duced in the neuroblastoma cell lines SH-EP/FOXO3 and
NB15/FOXO3 171 and 87 fold compared to untreated
controls and in the leukemia cell line CEM/FOXO3 50
fold (Figure 1a). To verify the observed DEPP regulation
by the transcription factor FOXO3, DEPP mRNA expres-
sion was further examined by quantitative RT-PCR in the
neuroblastoma cell lines NB1/FOXO3, NB3/FOXO3,
NB15/FOXO3 and SH-EP/FOXO3. Activation of the ec-
topic FOXO3(A3)ERtm via treatment with 4OHT led to
significant induction of DEPP mRNA expression up to
300 fold in SH-EP/FOXO3 and NB1/FOXO3 cells
(Figure 1b). To study the regulation of DEPP via FOXO3
at protein level, immunoblot analyses were performed.
Activation of FOXO3 by 4OHT treatment resulted in a
time-dependent increase of DEPP protein expression
(Figure 1c). As DEPP is described to be an insulin-
responsive gene [1] we performed quantitative RT-PCR
analysis to investigate the effects of insulin- and growth
factor signaling on DEPP expression. For this purpose,
SH-EP/FOXO3 and SH-EP/FOXO3-DBD cells [11] were
cultured under low serum conditions in presence or
absence of insulin. The SH-EP/FOXO3-DBD cell line
contains a FOXO3 DNA-binding domain (DBD) that sup-
presses FOXO3-induced transcription. Growth factor
withdrawal (media supplemented with 0.5% FCS) led to
significantly increased DEPP mRNA expression in SH-EP
cells, whereas treatment with insulin for 6 hours efficiently
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Figure 1 FOXO3 induces DEPP expression on mRNA and protein level. a) Regulation of DEPP (probe set 209183_s_at) as measured by
HG-U133 Plus 2.0 microarrays. Shown are fold-increases in expression between 3 hours 4OHT treated and untreated samples. b) Quantitative
RT-PCR of DEPP expression in SH-EP/FOXO3, NB1/FOXO3, NB3/FOXO3 and NB15/FOXO3 cells treated for 0, 3 and 6 hours with 100 nM 4OHT.
Shown are means ± s.e.m. of three independent experiments, each performed in triplicates. c) Immunoblot analyses of DEPP expression in SH-EP/
FOXO3, NB1/FOXO3, NB3/FOXO3 and NB15/FOXO3 cells treated with 100 nM 4OHT for 0, 4, 8, 16 and 24 hours. Alpha-Tubulin served as loading
control. d) Quantitative RT-PCR of DEPP expression in SH-EP/Ctr and SH-EP/FOXO3-DBD cells, which were cultured in 0.5% FCS for 24 hours and
then transferred into standard media (10% FCS) or treated with 10 nM insulin for another six hours. Shown are mean values ± s.e.m of three
independent experiments, each performed in triplicates; statistical analysis was done with the Student’s unpaired t-test, *P < 0.05; ***P < 0.01
compared to corresponding controls. e) Immunoblot analysis of DEPP expression in SH-EP/Ctr cells, which were cultured in 0.5% FCS for 24 hours.
GAPDH served as loading control.
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FOXO3-DBD cells strongly attenuated DEPP regulation
by growth factor withdrawal, suggesting that FOXO tran-
scription factors are essential for DEPP-induction during
serum starvation (Figure 1d). Growth factor withdrawal
also induces DEPP protein expression in SH-EP cells as
shown by immunoblot analysis (Figure 1e). Taken to-
gether, these results demonstrate that DEPP is a transcrip-
tional target of FOXO3 and regulated downstream of
insulin-signaling in neuroblastoma cells.
All three FOXO binding sites of the DEPP promoter
contribute to DEPP-induction by FOXO3
To study whether DEPP is a direct target of FOXO3 in
neuroblastoma cells, quantitative RT-PCR analysis of
SH-EP/FOXO3 cells treated with 75 nM 4OHT and with
10 μg/ml of the protein biosynthesis inhibitor cyclohexi-
mide (CHX) for 2 hours was performed. Treatment with
CHX did not prevent the induction of DEPP after
FOXO3 activation, which implies that induction of
DEPP by FOXO3 does not depend on de novo synthesis
of additional proteins, but is due to direct transcriptional
regulation (Figure 2a). To further test this hypothesis, a
DEPP promoter reporter luciferase assay was performed
in SH-EP/FOXO3 cells using a 1116 bp genomic frag-
ment of the promoter cloned upstream of firefly lucifer-
ase. The DEPP promoter contains three putative binding
sites for FOXO3 (Figure 2b), which were mutated for
this experiment. The first binding site for FOXO3 is lo-
cated at −537 (B1), the second at −179 (B2), and the
third at −151 (B3) relative to the start of the DEPP
mRNA [26].
Activation of ectopic FOXO3(A3)ERtm increased lucif-
erase activity approximately 9 fold (over untreated control).
Single mutations of each of the three FOXO3-binding sites
markedly reduced luciferase activity, indicating that each
site is necessary for efficient DEPP induction. Mutation of
B1 reduced the FOXO3 response to 28% of untreated cells,
whereas the mutated B2 site even further attenuated the
activity to 22%. Mutation of B3 exerted the strongest ef-
fect and lowered FOXO3-responsiveness of the DEPP
promoter to 15% of wildtype control. This was even less
than combined mutation of B1 and B2. Combined muta-
tion of all three FOXO3-binding sites (B1 + B2 + B3 MUT)
reduced luciferase activity to control level (Figure 2b). To
further strengthen these findings we performed chromatin
immunoprecipitation (ChIP) analysis on the FOXO3-
binding sites of the DEPP promoter (Figure 2c). These ex-
periments demonstrated that FOXO3 binds to B1 + B2
and, with highest efficiency, to the B3 consensus sequence,
which is consistent with the results obtained by the lucifer-
ase promoter reporter assay in Figure 2c. The consensus
sequences B1 and B2 are in close proximity, so one RT-
PCR primer pair for B1 + 2 was generated.These data demonstrate that FOXO3 activates all three
consensus elements in the DEPP promoter and that all
three FOXO3 binding sites are important for DEPP
regulation by FOXO3 in neuroblastoma cells.
Knockdown of DEPP reduces FOXO3-mediated apoptosis
FOXO3 activation has been shown to induce apoptosis
in neuroblastoma cells [5]. To study a possible effect of
DEPP on FOXO3-mediated apoptosis, the DEPP ex-
pression was knocked down by lentiviral expression of
DEPP-specific shRNA as shown in Figure 3a. Three in-
dividual clones of SH-EP/FOXO3-shDEPP (Figure 3a,
left panel) and bulk-selected NB15/FOXO3-shDEPP
(Figure 3a, right panel) were analyzed by immunoblot
and quantitative RT-PCR analysis. Propidium iodide-
(PI) FACS-analysis showed significantly reduced FOXO3-
mediated apoptosis in shRNA-expressing neuroblastoma
cell lines (Figure 3b).
We recently demonstrated that FOXO3-induced apop-
tosis is associated with and mediated by a biphasic accu-
mulation of ROS [11]. Thus we analyzed ROS steady
state levels in DEPP-knockdown cells and controls at the
specific time points by live-cell imaging. Knockdown of
DEPP almost completely prevented both, the primary
(4 hours and 12 hours) and secondary (16 and 48 hours)
ROS increase during FOXO3-activation in SH-EP/
FOXO3 and NB15/FOXO3 cells, respectively (Figure 3c).
In a previous study we observed that the oxidoreductase
p66/SHC1 is strongly phosphorylated at Ser36 during
FOXO3-induced ROS accumulation [11]. We therefore
performed immunoblot analysis of p66/SHC1 and pSer36-
p66/SHC1 protein in SH-EP/FOXO3-shCtr and SH-EP/
FOXO3-shDEPP cells (three individual clones), which
demonstrated that p66/SHC1 was not phosphorylated
after FOXO3 activation in DEPP-knockdown cells
(Figure 3d). This is consistent with the pronounced
effect of DEPP-knockdown on FOXO3-induced ROS
accumulation demonstrated by live-cell fluorescence
imaging analyses (Figure 3c).
We have previously shown that BCL2L11/Bim induc-
tion [11] and BIRC5/Survivin repression [10] are es-
sential for FOXO3-induced ROS accumulation and cell
death. Knockdown of DEPP neither prevented Bim in-
duction nor Survivin repression (data not shown), sug-
gesting that knockdown of DEPP does not interfere with
the initiation phase of ROS production but might affect
cellular ROS detoxification.
To directly study the effect of DEPP expression on
ROS production we generated stable cell lines that
conditionally express DEPP (SH-EP/tetDEPP) or EYFP-
tagged DEPP (SH-EP/tetEYFP-DEPP) in a tetracycline-
regulated manner (Figure 4a). DEPP overexpression on
its own slightly increased cellular ROS levels (Figure 4b)
but did not elevate cellular ROS to the level of FOXO3-
Figure 2 (See legend on next page.)
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Figure 2 DEPP is a direct transcriptional target of FOXO3. a) Quantitative RT-PCR of DEPP expression in SH-EP/FOXO3 cells, treated with
75 nM 4OHT for 2 hours to activate FOXO3(A3)ERtm or a combination of 4OHT and cycloheximide (CHX; 10 μg/ml), which was used to block
protein synthesis. Shown are mean values ± s.e.m. of three independent experiments, each performed in triplicates. b) The DEPP gene promoter
(−1116 bp relative to the transcription start) contains three putative binding sites for FOXO3, which are highlighted in the schematic representation.
A DEPP wild type promoter reporter plasmid and DEPP promoter reporter plasmids containing mutations of the three FOXO3-binding sites (B1, B2 and B3;
indicated as bold in sequence) were transfected into SH-EP/FOXO3 cells. The cells were treated with 100 nM 4OHT for 4 hours to activate FOXO3(A3)ERtm
and a luciferase-assay was performed. Direct binding of FOXO3 to the DEPP promoter leads to increased luciferase activity. The increase of the
luciferase signal was calculated as fold over untreated controls. Shown are mean values ± s.e.m. of three independent experiments, each performed in
duplicates; statistical analysis was done with the Student’s unpaired t-test, *P < 0.05; **P < 0.025 compared to corresponding controls. c) ChIP analysis
on the interaction between FOXO3 and the FOXO3 binding sites B1 + 2 and B3 of the DEPP promoter in SH-EP/FOXO3 cells treated with 100 nM
4OHT for 3 hours. Quantification was performed by quantitative RT-PCR with specific primers for B1 + 2 and B3. Shown are mean values of two
independent experiments, each performed in duplicates.
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pression alone did not increase phosphorylation of p66/
SHC1 (Figure 4d). This increase of cellular ROS by
conditional DEPP expression was not sufficient to in-
duce spontaneous apoptotic cell death as demonstrated
by PI-FACS analysis of SH-EP/tetDEPP and SH-EP/
tetEYFP-DEPP cells treated with doxycycline (doxy) for up
to 72 hours (Additional file 1: Figure S1). This suggests
that elevated DEPP expression does not constitute a death
signal per se, but rather changes the ability of neuroblast-
oma cells to detoxify ROS and is therefore necessary, but
not sufficient, for FOXO3-induced cell death.
DEPP regulates the catalase enzyme activity and thereby
the cellular ROS detoxification capacity
As DEPP knockdown efficiently reduced FOXO3-induced
ROS accumulation and DEPP overexpression by its own
increased steady state cellular ROS we next searched for a
possible explanation of this effect. Under normal condi-
tions low amounts of hydrogen peroxide (H2O2) are
mainly detoxified in the peroxisomes by the enzyme CAT/
catalase [13]. Catalase was also described as a direct tran-
scriptional target of FOXO transcription factors in various
cell types [16,17]. Protein sequence analysis suggests that
DEPP contains a peroxisomal-targeting-signal-2 (PTS2) in
its N-terminus that allows binding to the PEX7 receptor
[27] and might mediate the import of DEPP into peroxi-
somes [3]. As peroxisomes play an essential role in ROS
control especially in cells of neuronal origin [28] we ana-
lyzed peroxisomal function by measuring catalase enzyme
activity. Catalase activity was significantly reduced in SH-
EP/tetDEPP and SH-EP/tetEYFP-DEPP cells after 24 hours
of DEPP overexpression compared to SH-EP/tetEGFP
cells (Figure 5a). On the other hand, knockdown of DEPP
in SH-EP/FOXO3-shCtr cells resulted in significantly in-
creased catalase enzyme activity after 4OHT treatment
(Figure 5b). Both, in DEPP-overexpressing and DEPP-
knockdown cells, the amount of catalase protein level did
not change significantly (Figure 5a,b). We only observed
slightly increased catalase expression (1.45 fold compared
to untreated controls) after 24 hours of FOXO3 activationin SH-EP/FOXO3-shCtr cells and no regulation in the
SH-EP/FOXO3-shDEPP cell clones (Figure 5b). Next, we
analyzed protein expression of PPARG, which is described
to increase peroxisomal proliferation [29] and to directly
regulate catalase enzyme expression and activity [24,30].
We found protein levels of PPARG strongly upregulated
in SH-EP/FOXO3-shDEPP cells compared to SH-EP/
FOXO3-shCtr cells (Figure 5c), which is in line with the
increased catalase enzyme activity in these cells (Figure 5b).
These data suggest that cellular DEPP lowers the ability of
neuroblastoma cells to cope with cellular ROS as reflected
by reduced PPARG protein levels and catalase enzyme
activity.
To further test this hypothesis, we treated SH-EP/
tetEGFP, SH-EP/tetDEPP, SH-EP/tetEYFP-DEPP, SH-
EP/FOXO3-shDEPP and NB15/FOXO3-shDEPP cells
with H2O2 and measured cell death by flow cytometric
analysis of PI-stained nuclei. As shown in Figure 5d
SH-EP/tetDEPP and SH-EP/tetEYFP-DEPP cells (upper
panel) show higher H2O2-induced apoptosis, whereas
SH-EP/FOXO3-shDEPP (middle panel) and NB15/
FOXO3-shDEPP cells (lower panel) are significantly
more resistant to H2O2 treatment than controls. Etopo-
side treatment of SH-EP cells activates FOXO3, leads to
ROS accumulation [11] and significantly increases the
expression of endogenous DEPP even under conditions
of growth factor withdrawal (Figure 6a). We therefore
tested the effect of the DNA-damaging agent etoposide
on cells that overexpress DEPP in a tetracycline-
regulated manner. As shown in Figure 6b, DEPP-
overexpression led to a significant increase (P < 0.05) in
etoposide-induced apoptosis. Taken together these re-
sults demonstrate that DEPP reduces the cellular ROS
detoxification capacity, which in turn increases the sen-
sitivity to H2O2-and etoposide-induced apoptosis in
neuroblastoma cells.
DEPP localizes to mitochondria and peroxisomes in
neuroblastoma
DEPP was described to reside exclusively in the nucleus of
HEK293 cells [3], whereas Stepp et al. described DEPP as
Figure 3 (See legend on next page.)
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Figure 3 Knockdown of DEPP reduces FOXO3-mediated apoptosis. a) SH-EP/FOXO3 (SH-EP/FOXO3-shDEPP clone-10, -12 and -13; left panel)
and NB15/FOXO3 (NB15/FOXO3-shDEPP bulk; right panel) cells were infected with vectors coding for DEPP-specific shRNA. Knockdown efficiency
was verified by immunoblot (upper panel) and quantitative RT-PCR (lower panel). Cells were treated with 50 nM 4OHT to induce DEPP expression.
b) SH-EP/FOXO-shCtr and SH-EP/FOXO3-shDEPP-clone-10, -12 and -13 as well as NB15/FOXO3-shCtr and NB15/FOXO3-shDEPP (bulk) cells were
treated with 50 nM 4OHT for the indicated time points. PI-FACS analyses were performed to detect apoptotic cells. Shown is the mean ± s.e.m.
of three independent experiments; statistical analysis was done with the Student’s unpaired t-test, *P < 0.05; **P < 0.025; ***P < 0.01 compared to
corresponding controls. c) ROS accumulation was detected using MitoTrackerRed CM-H2XROS by live-cell imaging of SH-EP/FOXO3-shCtr and
SH-EP/FOXO3-shDEPP-clone-10, -12 and -13 as well as of NB15/FOXO3-shCtr and NB15/FOXO3-shDEPP (bulk) cells treated with 50 nM 4OHT for 4
and 16 hours and for 12 and 48 hours respectively to induce FOXO3 dependent biphasic ROS accumulation. Relative ROS staining was quantified
using the Axiovert200M fluorescence microscope software (Axiovision 4.6). Each panel represents the mean ± s.e.m. of 50 to 80 cells; statistical
analysis was done with the Student’s unpaired t-test, *P < 0.05; **P < 0.025 compared to corresponding controls. d) Immunoblot analysis of p66/
SHC1 and phosphorylated pSer36-p66/SHC1 expression in SH-EP/FOXO3-shCtr and SH-EP/FOXO3-shDEPP-clone-10, -12 and -13 cells treated with
50 nM 4OHT for the indicated time points. GAPDH served as loading control.
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[31]. To analyze the localization of DEPP in neurobla-
stoma cells we performed subcellular fractionation and
immunoblot analyses of SH-EP/tetEGFP and SH-EP/
tetEYFP-DEPP cells treated with 200 ng/ml doxy for
24 hours. As shown in Figure 7a (left panel) we found
DEPP mainly present in the cytoplasmic and not in the
nuclear fraction. Catalase, which is located in the perox-
isomes and the mitochondria, was also mainly present
in the cytoplasmic fraction. In a next step we treated
SH-EP/tetEYFP-DEPP cells with 200 ng/ml doxy for
24 hours, isolated the peroxisomes and performed im-
munoblot analysis of DEPP expression (Figure 7a, right
panel). By this subcellular fractionation experiment we
clearly demonstrated that a significant proportion of
DEPP is located in peroxisomes. To further analyze the
localization of DEPP we performed live cell confocal
imaging of SH-EP/tetEYFP-DEPP cells treated with
200 ng/ml doxy for 24 hours. Staining of the mitochon-
dria with MitotrackerRed/CMXRos and labeling of
peroxisomes by expression of a CellLight® Peroxisomes-
RFP marker protein clearly showed that the DEPP
protein co-localizes with both, mitochondria and perox-
isomes in neuroblastoma cells (Figure 7b). We detected
DEPP in SH-EP/EYFP-DEPP cells exclusively in the
mitochondria (Figure 7b, top two lines) or in the peroxi-
somes (Figure 7b, bottom line) and also simultaneously
in both organelles (Figure 7b, third line). Therefore the
live cell confocal imaging analyses indicate that the
DEPP protein is present in both organelles and may
translocate between mitochondria and peroxisomes,
which are cooperating and cross-talking [32] and are
both critical for the control of cellular ROS [15,33,34].
As DEPP lacks a mitochondrial targeting sequence but
contains a PTS2-signal at its N-terminus we next studied
whether DEPP is targeted to peroxisomes in a PTS2-
dependent manner via interaction with the PEX7 receptor
[27]. As shown in Figure 7c, DEPP co-immunopurifies
with the peroxisomal PEX7 receptor in SH-EP/tetDEPPcells treated with 200 ng/ml doxy for 24 hours. This is in
line with the subcellular fractionation assays (Figure 7a)
and the live cell imaging experiments (Figure 7b) dem-
onstrating that DEPP is present in peroxisomes.
Discussion
In this study we demonstrate for the first time that the
FOXO3-regulated gene DEPP impairs ROS detoxification
via the enzyme catalase and thereby increases the effects
of ROS on FOXO3-induced apoptosis in neuroblastoma
cells. Using Affymetrix gene expression profiling we iden-
tified DEPP as a FOXO3-regulated gene (Figure 1a) in
neuroblastoma as well as CEM-C7H2 leukemia cells and
found DEPP also induced by FOXO3 at the protein level
(Figure 1c). Recently it was reported that DEPP is tran-
scriptionally regulated by FOXO3 in human endothelial
cells and that FOXO3 binds to the DEPP promoter at
−151 (B1) and −179 (B2) relative to the transcription start
[26]. However, we found that the direct induction of DEPP
by FOXO3 is critically mediated via a third binding site
(B3), which is located −537 relative to the transcription
start of the DEPP mRNA in neuronal cells (Figure 2b).
Both, luciferase-reporter assays and ChIP analyses demon-
strate that FOXO3 binds to the three FOXO-consensus
sequences, among them most efficiently to the binding site
B3 (Figure 2c).
DEPP expression is inhibited by insulin-growth sig-
naling in neuroblastoma cells (Figure 1d). This is in
line with studies describing downregulation of DEPP
mRNA in mouse 3T3-L1 adipocytes, rat H4IIE and
human HepG2 hepatoma cells as a result of insulin
treatment [1,35]. However, in neuroblastoma cells DEPP-
induction by growth factor withdrawal is strongly reduced
in the presence of a dominant-negative FOXO mutant
suggesting that DEPP regulation by insulin/growth factor
signaling almost exclusively relies on FOXO transcription
factors (Figure 1d).
Currently there is little known about the physiological
function of DEPP as the few studies available focused on
Figure 4 Increased cellular ROS levels as a result of DEPP overexpression do not induce apoptosis. a) SH-EP/tetEGFP, SH-EP/tetDEPP and
SH-EP/tetEYFP-DEPP cells were treated with 200 ng/ml doxy for 24 hours to induce DEPP expression. The protein expression of DEPP was determined
by immunoblot. GAPDH served as loading control. b) SH-EP/tetEGFP, SH-EP/tetDEPP and SH-EP/tetEYFP-DEPP cells were treated with 200 ng/ml doxy
for 24 hours and ROS levels were detected by live-cell imaging using MitoTrackerRed CM-H2XROS. Relative ROS staining was quantified using the
Axiovert200M fluorescence microscope software. Each panel represents the mean ± s.e.m. of 60 to 70 cells; statistical analysis was done with the
Student’s unpaired t-test, *P < 0.05; **P < 0.025 compared to corresponding controls. c) SH-EP/tetDEPP and SH-EP/tetEYFP-DEPP cells were treated with
200 ng/ml doxy for 24 hours and SH-EP/FOXO3 cells with 50 nM 4OHT for 16 hours to induce FOXO3-mediated ROS accumulation. ROS levels were
detected by live-cell imaging using MitoTrackerRed Red CM-H2XROS. Relative ROS staining was quantified using the Axiovert200M fluorescence
microscope software. Each panel represents the mean ± s.e.m. of 10 to 20 cells. d) Cell lysates of SH-EP/tetEGFP, SH-EP/tetDEPP and SH-EP/tetEYFP-
DEPP cells treated with 200 ng/ml doxy for 16 and 24 hours were subjected to immunoblot analyses using antibodies directed against DEPP, p66/
SHC1 and phosphorylated pSer36-p66/SHC1. GAPDH served as loading control.
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found a prominent increase of DEPP expression in endo-
thelial cells when cultured under hypoxic conditions [26].
Similar results had been reported before in a malignant
glioma cell line [36]. These results may indicate a possible
role of DEPP during cellular stress response.
In this paper we demonstrate that the induction of DEPP
by FOXO3 contributes to FOXO3-induced cell death as
DEPP-knockdown significantly reduced FOXO3-mediated
apoptosis (Figure 3b). This death-protective effect ofDEPP-knockdown was associated with and possibly
also mediated by a marked reduction of FOXO3-
induced ROS accumulation (Figure 3c). FOXO3 causes
phosphorylation at Ser-36 of p66/SHC1, which corre-
lates with the time point of the second ROS accumula-
tion and apoptosis induction in SH-EP/FOXO3 cells
[11]. This phosphorylation of p66/SHC1 was almost
completely prevented by DEPP-knockdown (Figure 3d).
On the other hand, forced DEPP-overexpression in the
absence of FOXO3-induction slightly increased cellular
Figure 5 (See legend on next page.)
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Figure 5 DEPP impairs catalase activity and sensitizes to H2O2-induced apoptosis. a + b) A catalase enzyme activity assay was performed
in SH-EP/tetEGFP, SH-EP/tetDEPP, SH-EP/tetEYFP-DEPP cells treated with 200 ng/ml doxy (a) as well as of SH-EP/FOXO3-shCtr and SH-EP/FOXO3-
shDEPP-clone-10, -12 and -13 cells treated with 50 nM 4OHT (b) for 24 hours. The catalase enzyme activity was calculated between treated and
untreated cells (a). Shown are mean values ± s.e.m. of three independent experiments; statistical analysis was done with the Student’s unpaired
t-test, ***P < 0.01. Cell lysates of SH-EP/tetEGFP, and SH-EP/tetDEPP cells treated with 200 ng/ml doxy for 24 hours as well as of SH-EP/FOXO3-
shCtr and SH-EP/FOXO3-shDEPP-clone-10, -12 and -13 cells treated with 50 nM 4OHT for the indicated time points were subjected to immunoblot
analyses using an antibody against catalase. GAPDH served as loading control. Quantification of catalase protein expression normalized to GAPDH
(b) was done with the ImageJ 1.48 software. c) Immunoblot analysis of PPARG expression in SH-EP/FOXO3-shCtr and SH-EP/FOXO3-shDEPP-clone-10,
-12 and -13 cells treated with 50 nM 4OHT for 24 hours was performed. GAPDH served as loading control. d) SH-EP/tetEGFP, SH-EP/tetDEPP and
SH-EP/tetEYFP-DEPP cells (upper panel) were pre-treated with 200 ng/ml doxy for 24 hours and then incubated with 15 μM H2O2 for one hour.
SH-EP/FOXO3-shCtr and SH-EP/FOXO3-shDEPP clone-10, -12 and -13 (middle panel) and NB15/FOXO3-shCtr and NB15/FOXO3-shDEPP (bulk, lower
panel) were treated with 25 μM H2O2 for 1 hour. PI-FACS analyses were performed to detect apoptotic cells. Shown are mean values ± s.e.m. of
three independent experiments; statistical analysis was done with the Student’s unpaired t-test, *P < 0.05, ***P < 0.01.
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ROS to the level of FOXO3-induced ROS formation.
This might explain why DEPP-overexpression did not
lead to phosphorylation of p66/SHC1 and apoptosis in-
duction by its own (Figure 4). These combined dataFigure 6 DEPP overexpression leads to a sensitization to etoposide-in
starvation (0.5% FCS) for 24 hours and treated with 20 μg/ml etoposide for
statistical analysis was done with the Student’s unpaired t-test, ***P < 0.01.
etoposide alone and in combination with 200 ng/ml doxy for 48 hours. PI-
mean values ± s.e.m. of three independent experiments; statistical analysissuggest that in neuronal cells DEPP may act as a
sensitizer for cellular ROS that affects ROS accumula-
tion and/or detoxification.
DEPP contains a PTS2 signal sequence at its N-terminus
[3] suggesting that this protein might get imported intoduced apoptosis. a) Real-time PCR of SH-EP cells set under serum
6 hours. Shown are means ± s.e.m. of three independent experiments;
b) SH-EP/tetEGFP and SH-EP/tetDEPP cells were treated with 20 μg/ml
FACS analyses were performed to detect apoptotic cells. Shown are
was done with the Student’s unpaired t-test, *P < 0.05, **P < 0.025.
Figure 7 (See legend on next page.)
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Figure 7 DEPP is located in mitochondria and peroxisomes. a) SH-EP/tetEGFP and SH-EP/tetEYFP-DEPP cells were treated with 200 ng/ml
doxy for 24 hours and subjected to subcellular fractionation. The protein levels of DEPP, GFP and catalase in the cytosolic and the nuclear fraction
were determined by immunoblot. Alpha-Tubulin (cytosolic) and Lamin (nuclear) were used to control the purity of the fractions (left panel). The
peroxisomal fraction of SH-EP/tetEYFP-DEPP cells treated with 200 ng/ml doxy for 24 hours was separated using a peroxisome isolation kit
(PEROX1, Sigma). DEPP protein expression was determined by immunoblot. Catalase (peroxisomes) and CoxIV (mitochondria) were used to
control the purity of the peroxisomal fraction (right panel). b) SH-EP/tetEYFP-DEPP cells were grown on eight-well chambered cover glasses,
treated with 200 ng/ml doxy for 24 hours and analyzed by live confocal microscopy. Mitochondria were stained using the specific mitochondrial
probe MitoTrackerRed/CMXRos (30 nM). Peroxisomal staining was performed with a CellLight® Peroxisomes-RFP fusion construct. c) SH-EP/tetDEPP
cells treated with 200 ng/ml doxy for 24 hours were subjected to CoIP analysis with a Pierce Crosslink Magnetic IP/Co-IP kit to investigate
whether the DEPP protein co-immunopurifies with PEX7-cross-linked beads. The expression of PEX7 and DEPP was determined by immunoblot.
Alpha-Tubulin served as loading control.
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stress response via the enzyme catalase [15]. Catalase ac-
tivity was reduced in response to DEPP overexpression
and significantly increased in DEPP-knockdown cells,
although catalase was not regulated on protein level
(Figure 5a,b). In parallel, the expression of PPARG was
strongly upregulated in DEPP-knockdown cells. This tran-
scription factor is critical for the control of cellular ROS
levels as it directly regulates several different ROS-
detoxifying enzymes, including catalase [20]. PPARG acts
as a regulator of peroxisomal proliferation and its upre-
gulation may explain the marked resistance of DEPP-
knockdown cells towards H2O2 (Figure 5d). This repression
by FOXO3 (Figure 5c) is consistent with earlier studies
that demonstrated direct transcriptional repression of the
PPARG promoter by FOXO1, which recognizes the same
consensus sequence as FOXO3 [21,22]. PPARG on the
other hand can also repress FOXO transcriptional activity.
Beta-Catenin, which interacts with both, FOXO and
PPARG via its TCF/Lef1 binding site, represses PPARG
expression (reviewed in [24]). We found beta-Catenin ex-
pression up-regulated as a result of DEPP overexpression
(Additional file 2: Figure S2). One explanation for this
phenomenon could be that DEPP stimulates the Wnt-
pathway via its PPPSP motif [3,23,25]. As beta-Catenin
mediates repression of PPARG, this could explain the ob-
served increase in PPARG expression in DEPP-knockdown
cells, which in turn increases ROS resistance and further
shuts down FOXO3 transcriptional activity. When ectopi-
cally expressed, FOXO3 is activated, this circuit is
interrupted and PPARG is repressed (Figure 5c), which
also opens an avenue for ROS-accumulation during
FOXO3-induced cell death. This possible link between
DEPP, beta-Catenin and PPARG protein expression
will be investigated in a separate project.
Reduced catalase activity results in increased levels of
intracellular H2O2 and subsequent cellular damage. Fur-
thermore it was described that the increase in mitochon-
drial oxidative damage and the decrease in mitochondrial
function occurs rapidly following the inhibition of per-
oxisomal catalase [15]. H2O2 causes oxidative damagethroughout the cell and mainly impairs mitochondria,
which in turn leads to further ROS accumulation. In
particular H2O2, which is the species of ROS that accu-
mulates upon catalase inhibition, freely diffuses across bio-
logical membranes, including aquaporin channels present
in the mitochondrial membranes [37]. Consistent with the
changes in catalase activity, we found that DEPP overex-
pression increased ROS levels and H2O2-induced apop-
tosis, whereas DEPP-knockdown cells were more resistant
to H2O2 treatment (Figure 5d).
In transient overexpression studies using HEK293T cells
DEPP was reported to localize to the nucleus [3] and not
to peroxisomes as predicted by the presence of a PTS2 sig-
nal in the N-terminus. Using subcellular fractionation
(Figure 7a) and live cell confocal imaging with fluorescent
peroxisomal and mitochondrial probes (Figure 7b) we
demonstrate that in neuroblastoma cells DEPP is a cyto-
plasmatic protein that localizes in part to peroxisomes and
to mitochondrial structures. Co-immunoprecipitation ana-
lyses (Figure 7c) indicate that DEPP is targeted to peroxi-
somes in a PTS2-dependent manner as it interacts with
the PEX7 receptor.
As these two cell organelles are the key regulators of
cellular stress response and ROS generation/detoxifica-
tion, DEPP might directly modulate ROS at these
organelles.
The above data predict that DEPP may act as a
sensitizer for all forms of apoptotic cell death that in-
volve accumulation of ROS as a second messenger. In-
deed, this is true for FOXO3-induced apoptosis, where
knockdown of DEPP significantly lowered FOXO3-
induced cell death (Figure 3b). DEPP overexpression on
the other hand increased etoposide-induced apoptosis.
Of note, etoposide also activates endogenous DEPP ex-
pression, thereby limiting the visible effect of ectopic ex-
pression on death sensitivity (Figure 6). Importantly,
induction of DEPP by etoposide and death-sensitization
by DEPP are in line with our previous work, which dem-
onstrated that etoposide-induced cell death depends on
the activation of FOXO3 and the subsequent induction
of cellular ROS in neuronal cells [11].
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In neuroblastoma, FOXO3 gets activated as a result of
cellular stress response, which leads to cellular ROS for-
mation and upregulation of DEPP expression. The com-
bined data clearly demonstrate for the first time that
DEPP regulates cellular ROS levels, reduces catalase en-
zyme activity and may thereby support or even amplify
ROS accumulation during FOXO3-induced apoptosis.Methods
Cell lines, culture conditions, and reagents
The neuroblastoma cell lines STA-NB1, STA-NB3 and
STA-NB15 were isolated at the St. Anna Children’s
Hospital (Vienna, Austria) and are termed NB1, NB3 and
NB15, respectively [38]. SH-EP cells were kindly provided
by N. Gross, Lausanne, Switzerland [39]. The acute
lymphoblastic leukemia cell line CEM/C7H2, a subclone
of the CCRF-CEM cell line and all other cell lines were
cultured in RPMI 1640 (Lonza, Basel, Switzerland) con-
taining 10% fetal calf serum, 100 U/ml penicillin, 100 μg/
ml streptomycin and 2 mM L-glutamine (Gibco BRL,
Paisley, GB) at 5% CO2 and 37°C in saturated humidity.
PhoenixTM packaging cells for helper-free production of
amphotropic retroviruses [40] and HEK293T packaging
cells for production of lentiviruses were cultured in
DMEM (Lonza, Basel, Switzerland). Cell culture was
tested routinely for mycoplasma contamination using
the VenorRGeM-mycoplasma detection kit (Minerva
Biolabs, Germany). All reagents were purchased from
Sigma-Aldrich (Vienna, Austria) unless indicated other-
wise. For each experiment, mid-log-phase cultures were
seeded in fresh medium.Retroviral and lentiviral expression vectors
The vectors pLIB-FOXO3(A3)-ER-iresNeo, pQ-tetCMV-
SV40-Neo and pQ-tetCMV-EGFP-SV40-Neo have been
described previously [5,41,42]. For conditional gene ex-
pression, the coding region of DEPP was amplified from
human cDNA with primers containing appropriate re-
striction enzyme sites. The fragment was inserted into
the MfeI and XhoI sites of the tet-regulated expression
plasmid pQ-tetCMV-SV40-Neo generating the plasmid
pQ-tetCMV-DEPP-SV40-Neo and into the MfeI and
XhoI sites of the EYFP-containing plasmid pQ-tetCMV-
EYFP-SV40-Neo (pQ-tetCMV-EYFP-DEPP-SV40-Neo).
The lentiviral vectors coding for human DEPP-specific
shRNA and the control vector pLKO.1 were obtained
from Sigma-Aldrich (Vienna, Austria). pLIB-mycTag-
FOXO3-DBD-iresPuro was constructed by inserting the
FOXO3-DBD fragment from pSG5-MycTag-FOXO3-
DBD [43] into the EcoR1 and Sal1 sites of the pLIB-
MCS2-iresPuro plasmid [41].Production of retroviruses and lentiviruses for infection of
neuroblastoma and leukemia cells
6 × 105 Phoenix™ packaging cells were transfected with 2
μg of retroviral vectors and 1 μg of a plasmid coding for
VSV-G protein using Lipofectamine2000 (Invitrogen,
Carlsbad, USA). For production of lentiviruses 6.5 × 105
HEK293T cells were transfected with 1.6 μg pLKO.1-
shDEPP plasmids coding DEPP-specific shRNAs (Sigma-
Aldrich, Vienna, Austria) and the packaging plasmid
pCMV 8.91 (kindly provided by D. Trono, EPFL, Lausanne).
After 48 hours the virus-containing supernatants were
filtered through 0.22 μm syringe filters (Sartorius,
Goettingen, Germany) and incubated with the target cells
for at least 6 hours. SH-EP/FOXO3 and NB15/FOXO3
cells were infected to generate SH-EP/FOXO3-Ctr, SH-EP/
FOXO3-shDEPP (clone-10, -12 and -13), NB15/FOXO3-
Ctr and NB15/FOXO3-shDEPP (bulk-selected) cells.
pQ-tetCMV-DEPP-SV40-Neo, pQ-tetCMV-EYFP-DEPP-
SV40-Neo, and pQ-tetCMV-EGFP-SV40-Neo supernatants
were used to generate SH-EP/tetDEPP, SH-EP/tetEYFP-
DEPP and SH-EP/tetEGFP cells for doxycycline-inducible
DEPP and EGFP expression using the “tet-on” system [41].
pLIB-mycTag-FOXO3-DBD-iresPuro supernatants were
used to infect SH-EP cells (SH-EP/FOXO3-DBD) [11].
Microarray data set generation and analysis
Generation of the Affymetrix microarray data set was per-
formed at the Expression Profiling Unit of the Medical
University Innsbruck according to the manufacturer’s pro-
tocols. The procedure and protocols have been described
elsewhere [44]. The data analysis was performed in R (ver-
sion). Raw data has been pre-processed using the GCRMA
method [45]. Raw and pre-processed data has been depos-
ited at the Gene Expression Omnibus (GEO accession
number GSE53046).
Site directed mutagenesis
A luciferase reporter plasmid containing the DEPP pro-
moter (−1116 bp relative to the transcription start site) was
purchased from Switchgear Genomics (Menlo Park, USA).
The three putative FOXO3 binding sites in the DEPP pro-
moter [26] (named B1, B2 and B3) were mutated by sited
directed mutagenesis PCR using circular mutagenesis. The
first site is located at −537 to −530 (B1), the second at −179
to −172 (B2), and the third at −151 to −143 (B3) relative to








CTG/ Ta = 58°C, 18 PCR-cycles). Promoter reporter
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B1 + B2 and B1 + B2 + B3 were used for luciferase activ-
ity analysis.
Quantitative RT-PCR analysis
To quantify DEPP mRNA levels, we designed “real-time”
RT-PCR assays, using GAPDH as reference gene. NB1/
FOXO3, NB3/FOXO3, NB15/FOXO3 and SH-EP/FOXO3
cells were cultured in the presence of 100 nM 4OHT for
the times indicated to activate the FOXO3(A3)ERtm
transgene. Total RNA was prepared from 5 × 106 cells using
TRIzolTM Reagent (Invitrogen, Carlsbad, USA) according
to the manufacturer’s instructions. cDNA was synthesized
from 1 μg of total RNA using the Revert H Minus First
Strand cDNA Synthesis Kit (Thermo Scientific, Huntsville,
USA). Quantitative RT-PCR was performed as described
previously [11] using DEPP (forward ACTGTCCCTGCT
CATCCATTCTC and reverse AGTCATCCAGGCTAG
GAGAGGG) and GAPDH-specific oligonucleotides (for-
ward TGTTCGTCATGGGTGTGAACC and reverse
GCAGTGATGGCATGGACTGTG). After normalization
on GAPDH expression, regulation was calculated between
treated and untreated cells.
Immunoblotting and subcellular fractionation
Immunoblot analysis and subcellular fractionation were
performed as described previously [11]. The membranes
were incubated with primary antibodies specific for DEPP,
PEX7, GAPDH (Novus, Littleton, USA), Bim, beta-Catenin
(BD Biosciences, Heidelberg, Germany), Catalase (Calbio-
chem, San Diego, USA), p66/SHC1, phosphorylated pSer36-
p66/SHC1 (Abcam, Cambridge, UK), PPARG, Lamin,
CoxIV (Cell Signaling,Danvers, USA), GFP (Sigma-Aldrich,
Vienna,Austria) and alpha-Tubulin (Oncogene Research
Products, Boston,USA).
After incubation with anti-mouse, anti-rat or anti-rabbit
horseradish-peroxidase-conjugated secondary antibodies
the blots were analyzed by enhanced chemiluminescence
substrate (GE-Healthcare, Vienna, Austria) according to
the manufacturer’s instructions and detected with an
AutoChemiSystem (UVP, Cambridge, GB). Quantification
of protein expression was done with the ImageJ 1.48 soft-
ware, according to the ImageJ User Guide (http://imagej.
nih.gov/ij/index.html).
Peroxisomal separation
The peroxisomal fraction was isolated by using the per-
oxisome isolation kit (PEROX1; Sigma-Aldrich, Vienna,
Austria), according to the instructions of the manufac-
turer. Briefly, 4 × 108 SH-EP/tetEYFP-DEPP cells were
treated with 200 ng/ml doxy for 24 hours, harvested, re-
suspended in peroxisome extraction buffer and homoge-
nized in a dounce homogenizer. Next, the cells were
centrifuged for 10 minutes at 1000 g. The supernatantrepresents the “input fraction”. After several centrifuga-
tion steps according to the manufacturer’s protocol, the
pellet was collected in 1x peroxisome extraction buffer.
Isolation of the peroxisomes was done on a density gra-
dient. By a centrifugation step for 1.5 hours at 100.000 g
the purified peroxisomes were separated from the mito-
chondria. To measure the purity of the peroxisomal frac-
tion immunoblot analyses with catalase (peroxisomes)
and CoxIV antibodies (mitochondria) were performed.
Co-immunoprecipitation analysis (CoIP)
CoIP was performed with a Pierce Crosslink Magnetic
IP/Co-IP kit (Pierce, Rockford, USA) according to the
instructions of the manufacturer. Briefly, 5 μg of PEX7
antibody (Novus, Littleton, USA) were covalently cross-
linked to 25 μl of A/G magnetic beads. The prepared
beads as well as beads without cross-linked antibody (IP
Ctr) were incubated with extracts from SH-EP/tetDEPP
cells treated with 200 ng/ml doxy for 24 hours, washed
to remove non-bound material and eluted in a low-pH
elution buffer that dissociates bound antigen from the
antibody- linked beads. The total protein (TP) and the
eluates (IP and IP Ctr) were analyzed via immunoblot.
Chromatin immunoprecipitation assay (ChIP)
ChIP was performed with a Millipore Magna ChIP Kit
(Millipore, Darmstadt, Germany) according to the instruc-
tions of the manufacturer. Approximately 2 × 107 SH-EP/
FOXO3 cells and 20 μl of the protein G beads coupled
with 5 μl of anti-FOXO3 antibody (Santa Cruz, Dallas,
USA) were used for each preparation. For quantification
of FOXO3 binding to the DEPP promoter quantitative real
time RT-PCR was performed with primers for the binding
sites B1 + B2 (forward AAAACAGCTTGGTGGGCGGG
and reverse AACAAGCTTTGGGGCAGGGG) and B3
(forward CTGCTCCTAGGAGAGACACACCCTG and
reverse CTGCTACGTTTGCTGTGCTTAGTGC).
Determination of apoptosis by flow cytometry
Apoptosis was measured by staining the cells with
propidium-iodide (PI) and forward/sideward scatter ana-
lysis using a CytomicsFC-500 Beckman Coulter. 2 × 105
cells were harvested and incubated in 500 μl hypotonic
PI solution containing 0.1% Triton X-100 for 4 to 6 hours
at 4°C. Stained nuclei in the sub-G1 marker window
were considered to represent apoptotic cells [46].
Luciferase activity assay
To determine direct regulation of the DEPP-promoter
by FOXO3, promoter plasmids containing the DEPP-
promoter (1116 bp) and mutated variants were transiently
transfected into SH-EP/FOXO3 cells using the JetPrime®
Reagent (Polyplus, Berkeley, USA) according to the ma-
nufacturer’s instructions. Subsequently the cells were
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activate the FOXO3 transcription factor. Luciferase activ-
ity was measured with a Luciferase Assay System kit (Pro-
mega, Fitchburg, USA) according to the manufacturer’s
instructions. The reactions were done in duplicates and
repeated three times. Luciferase activity was calculated be-
tween treated and untreated cells.
Live cell ROS staining
For ROS measurements, cells were grown on LabTek
Chamber Slides™ (NalgeNunc International, Rochester,
USA) coated with 0.1 mg/ml collagen and incubated
with reduced MitoTrackerRed CM-H2XROS (Invitrogen,
Carlsbad, CA, USA) for 20 minutes according to the
manufacturer’s instructions (final concentration 500 nM).
Images were collected with an Axiovert200M microscope
equipped with filters for EYFP (exitation: BP500/20, emis-
sion: BP535/30) and RFP (excitation: BP546/12, emission:
LP590) and a 63x-oil objective (Zeiss, Vienna, Austria).
Live confocal imaging
Cells were grown on LabTek Chamber Slides™ (NalgeNunc
International, Rochester, USA) coated with 0.1 mg/ml col-
lagen and incubated for 15 minutes with 30 nM Mito-
TrackerRed CMX-Ros (Invitrogen, Carlsbad, USA) to stain
mitochondria. Peroxisomes were labelled with the Cell-
Light® Peroxisome-RFP vector (Life Technologies, Carlsbad,
USA) according to the manufacturer’s instructions. Cells
were analyzed by live confocal microscopy using an inverted
microscope (Zeiss Observer.Z1; Zeiss, Oberkochen,
Germany) in combination with a spinning disc confocal
system (UltraVIEW VoX; Perkin Elmer, Waltham, MA,
USA). All images were acquired using a 63× oil immersion
objective.
Catalase assay
Catalase enzyme activity was analyzed with a Catalase
Assay Kit (Abcam, Cambridge, UK). Cells were cultured
in the presence of 50 nM 4OHT (SH-EP/FOXO3-
shDEPP) or 200 ng/ml doxy (SH-EP/tetEGFP, SH-EP/
tetDEPP, SH-EP/tetEYFP-DEPP) for the times indicated.
1 × 106 cells were harvested and used for the enzyme
assay according to the manufacturer’s instructions. After
30 minutes incubation time the reaction was stopped and
the optical density was measured with a Benchmark Mi-
croplate Reader (BioRad Laboratories, Munich, Germany).
Catalase enzyme activity was calculated between treated
and untreated cells.
Additional files
Additional file 1: Figure S1. Elevated DEPP expression does not cause
cellular apoptosis per se. SH-EP/tetDEPP and SH-EP/tetEYFP-DEPP cells
were treated with 200 ng/ml doxy for the indicated time points. PI-FACSanalyses were performed to detect apoptotic cells. Shown are means ± s.
e.m. of three independent experiments.
Additional file 2: Figure S2. DEPP overexpression increases beta-
Catenin protein levels. SH-EP/tetEGFP, SH-EP/tetDEPP and SH-EP/tetEYFP-
DEPP cells were treated with 200 ng/ml doxy for 24 hours to induce
DEPP expression. The protein expression of DEPP and beta-Catenin was
determined by immunoblot. GAPDH served as loading control.
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